FIELD: biotechnology.
SUBSTANCE: invention relates to coagulation factor IX (FIX) conjugates, and can be used in medicine for the prevention or treatment of diseases associated with congenital or acquired FIX deficiency. A conjugate containing a FIX fusion protein and a 40 kDa polyethylene glycol attached to the C-terminus of the fusion protein is proposed. The fusion protein contains an active FIX group and a fusion partner (FP) and is represented by the structure FIX-L1-Fс-L2-P, where FIX is a full-length human coagulation factor IX, the fusion partner is an immunoglobulin Fc fragment from human IgG1 with point mutation N297A, L1 and L2 are peptide linkers, and P is an amino acid fragment containing the LPETGG sortase recognition site.
EFFECT: invention provides obtaining a FIX-based conjugate with an increased half-life in the bloodstream.
9 cl, 6 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
